Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Colorectal Neoplasms 3Neoplasms 2Multiple Myeloma 2Lymphoma 2Solid Tumors, Adult 1Recurrence 1Pancreatic Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lung Neoplasms 1Diarrhea 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Ductal, Breast 1Breast Neoplasms 1

Interventions

Paclitaxel 11Carboplatin 8Radiotherapy 7Letrozole 7Cyclophosphamide 7Trastuzumab 5Chemotherapy, Adjuvant 5Doxorubicin 4Brachytherapy 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4atamestane 3Toremifene 3Tamoxifen 3Radiotherapy, Conformal 3Magnetic Resonance Spectroscopy 3Epirubicin 3Docetaxel 3Cryosurgery 3Cisplatin 3pertuzumab 2Surgical Procedures, Operative 2Radiation 2Lapatinib 2Fulvestrant 2Estrogen Receptor Modulators 2Cryotherapy 2Capecitabine 2Biopsy 2Aromatase Inhibitors 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Ductal, Breast × Drugs, Investigational × Clear all
NCT03113825 2021-06-11

Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

Avelas Biosciences, Inc.

Phase 2 Completed
92 enrolled
Breast

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Carcinoma, Ductal, Breast

Data powered by HemOnc (CC BY 4.0) Colophon âš¡